Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Acadia Pharmaceuticals Inc. on May 29, 2026. The filing details the outcomes of shareholder votes regarding director elections, executive compensation, auditor ratification, and an amendment to the company's equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
The following matters were approved or ratified by stockholders at the Annual Meeting:
- Director Elections: Three Class I directors were elected to serve until the 2029 Annual Meeting:
- James M. Daly: 146,927,745 votes For; 3,521,002 Withheld.
- Edmund P. Harrigan, M.D.: 128,460,130 votes For; 21,988,617 Withheld.
- Adora Ndu, Pharm.D., J.D.: 134,540,552 votes For; 15,908,195 Withheld.
- Executive Compensation: Advisory approval of named executive officer compensation was granted with 148,265,173 votes For and 1,911,358 votes Against.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 157,409,378 votes For and 3,319,736 votes Against.
- Equity Plan Amendment: Stockholders approved an amendment to the 2024 Equity Incentive Plan to increase the aggregate number of shares authorized for issuance by 5,209,670 shares. The vote was 147,258,860 For and 3,096,136 Against.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, specific risks, contingencies, or unusual items. The document focuses strictly on the procedural results of the Annual Meeting.
Investor Verification Checklist
- Verify the full text of the amended 2024 Equity Incentive Plan (Exhibit 10.1) to understand the specific terms of the 5,209,670 share increase.
- Review the definitive proxy statement filed on April 24, 2026, for detailed descriptions of the director nominees and executive compensation rationale.
- Confirm the tenure of the newly elected Class I directors, which extends until the 2029 Annual Meeting.
- Note that the filing does not update financial performance; refer to the most recent 10-K or 10-Q for financial metrics.